Open Access

Erratum to: Per-capita consumption of analgesics: a nine-country survey over 20 years

The Journal of Headache and Pain20089:65

https://doi.org/10.1007/s10194-008-0065-3

Published: 20 August 2008

The original article was published in The Journal of Headache and Pain 2008 9:46

Erratum to: J Headache Pain DOI 10.1007/s10194-008-0046-6

This article unfortunately contained errors in two places.

1. The two columns of data in Table 1 were under the wrong headings. The correct version of Table 1 is given here:
Table 1

Relative proportions of standardised medication units (SU) among different countries comparing weighted and unweighted proportions

Relative proportions of ASA consumption

Unweighted (%)

Weighted by mg ASA (%)

USA

58.2

48.3

Germany (West)

16.0

19.7

Canada

12.2

10.7

France

9.7

16.7

Sweden

1.1

1.3

Switzerland

0.7

0.8

Austria

1.7

1.8

Belgium

0.3

0.6

Australia

0.1

0.1

Total 9 countries

100

100

100% = overall consumption of acetylic salicylic acid (ASA) among nine countries

2. Incorrect percentages were given in the last paragraph of the “Results” section, immediately before the “Discussion”. The corrected paragraph is as follows:

In 2005 in the prescription (Rx) group of N2B analgesics, combination products accounted for approx. 33% of all Rx analgesics in terms of SU. The most important combinations are tilidine plus naloxone (14% of all SU in the Rx group), followed by codeine plus paracetamol (12%). The predominating single products in the Rx group are metamizole (36%) and tramadol (21%). Growth in the Rx group can be seen for both the combinations named and the single products.

Notes

Authors’ Affiliations

(1)
Department of Neurology, University Duisburg-Essen
(2)
Boehringer Ingelheim Pharma GmbH & Co. KG

Copyright

© Springer-Verlag 2008